S&P Futures
4,364.50 -39.25 (-0.89%) Dow Futures
34,018.00 -235.00 (-0.69%) Nasdaq Futures
14,332.75 -168.25 (-1.16%) Russell 2000 Futures
2,011.00 -20.70 (-1.02%) Crude Oil
83.57 +0.26 (+0.31%) Gold
1,842.50 +0.80 (+0.04%)
Voyager Therapeutics, Inc. (VYGR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.8300 |
| Open | 2.8000 |
| Bid | 2.8500 x 1100 |
| Ask | 2.9000 x 1400 |
| Day's Range | 2.6000 - 2.8800 |
| 52 Week Range | 2.4600 - 9.0700 |
| Volume | |
| Avg. Volume | 575,574 |
| Market Cap | 108.179M |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4730 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
Fair Value
Related Research
- Voyager Therapeutics, Inc.CYTK: Lowering target price to $35.00CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.RatingFair ValueEconomic Moat6 days agoArgus Research
- Simply Wall St.
Shareholders in Voyager Therapeutics (NASDAQ:VYGR) are in the red if they invested five years ago
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...
- GlobeNewswire
Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
Novel intravenous (IV) vectorized antibody approach designed to activate innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor progression in CNS Proprietary TRACER™ capsid screening technology enables broad expression of vectorized antibody in mouse brain TRACER AAV vector encoding anti-HER2 antibody demonstrated tumor reduction across multiple mouse models and survival benefit CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYG
- American City Business Journals
These 40 Mass. companies made the new Deloitte Fast 500 list
The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.
